Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 4, 2004, Pages 780-784

  Fuhrmann, Valentin ^a   Schenk, Peter ^a   Jaeger, Walter ^b   Ahmed, Salwa ^b   Thalhammer, Florian ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antibiotics; Dosage recommendations; Intensive care patients; Renal failure; Renal replacement therapy

Indexed keywords

CATECHOLAMINE DERIVATIVE; DANAPAROID; HEPARIN; KETAMINE; MIDAZOLAM; MORPHINE DERIVATIVE; MOXIFLOXACIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANURIA; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTENSIVE CARE UNIT; MALE; RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIAL INFECTIONS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMODIAFILTRATION; HEMODIALYSIS SOLUTIONS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; QUINOLINES; SEVERITY OF ILLNESS INDEX;

EID: 6344282916     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh421     Document Type: Article

References (21)

1. Dalhoff, A., Peterson, U. & Endermann, R. (1996). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42, 410-25.
2. Zhanel, G. G., Ennis, K., Vercaugne, L. et al. (2002). A critical review of the fluoroquinolones. Drugs 62, 13-59.
3. Pestova, E., Millichap, J. J., Noskin, G. A. et al. (2000). Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. Journal of Antimicrobial Chemotherapy 45, 583-90.
4. Stass, H. & Kubitza, D. (1999). Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. Journal of Antimicrobial Chemotherapy 43, Suppl. B, 83-90.
5. Wise, R., Andrews, J. M., Marshall, G. et al. (1999). Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral and intravenous administration. Antimicrobial Agents and Chemotherapy 43, 1508-10.
6. Stass, H., Kubitza, D., Halabi, A. et al. (2002). Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. British Journal of Clinical Pharmacology 53, 232-7.
7. Cotterill, S. (1995). Antimicrobial prescribing in patients on haemofiltration. Journal of Antimicrobial Chemotherapy 36, 773-80.
8. Golper, T. A. & Marx, M. A. (1998). Drug adjustments during continuous renal replacement therapies. Kidney International 53 Suppl. 66, 165-8.
9. Stass, H., Dalhoff, A., Kubitza, D. et al. (1998). Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrobial Agents and Chemotherapy 42, 2060-5.
10. Muhl, E., Martens, T., Iven, H. et al. (2000). Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. European Journal of Clinical Pharmacology 56, 671-8.
11. Ba, B. B., Etienne, R., Ducint, D. et al. (2001). Determination of moxifloxacin in growth media by high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 15, 107-12.
12. Lubasch, A., Keller, I., Corner, K. et al. (2000). Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrobial Agents and Chemotherapy 44, 2600-3.
13. Sullivan, J. T., Woodruff, M., Lettieri, J. et al. (1999). Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrobial Agents and Chemotherapy 43, 2793-7.
14. Simon, N., Sampol, E., Albanese, J. et al. (2003). Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. Clinical Pharmacology and Therapeutics 74, 353-63.
15. Stass, H., Dammer, S., Kubitza, D. et al. (2002). No dose adjustment is needed for patients undergoing hemodialysis (HD) receiving oral moxifloxacin (MFX). In Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract A-1383, p. 17. American Society for Microbiology, Washington, DC, USA.
16. Stass, H., Dammer, S., Kubitza, D. et al. (2002). Influence of continuous ambulatory peritoneal dialysis (CAPD) on the kinetics of oral moxifloxacin (MFX). In Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract A-1384, p. 17. American Society for Microbiology, Washington, DC, USA.
17. Lister, P. D. & Sanders, C. C. (1999). Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 43, 79-86.
18. Buxbaum, A., Straschil, U., Moser, C. et al. (1999). Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Journal of Antimicrobial Chemotherapy 43, Suppl. B, 13-8.
19. Malone, R., Fish, D., Abraham, E. et al. (2001). Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrobial Agents and Chemotherapy 45, 2949-54.
20. Traunmüller, F., Thalhammer-Scherrer, R., Locker, G. J. et al. (2001). Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. Journal of Antimicrobial Chemotherapy 47, 229-31.
21. Fuhrmann, V., Mittermayer, C., Schiefermeier, M. et al. (2004). Pharmakokinetik von ciprofloxacin während kontinuierlicher venovenöser hämofiltration. Wiener Klinische Wochenschrift 116, A 4.